23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Novartis Pharmaceuticals
2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.
Novartis Pharmaceuticals
Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase.
Novartis Pharmaceuticals
Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.
Novartis Pharmaceuticals
Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1.
Novartis Pharmaceuticals
Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2.
Novartis Pharmaceuticals
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.
Novartis Pharmaceuticals
Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.
Novartis Pharmaceuticals
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
Bayer Pharma Aktiengesellschaft
Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
Bayer Pharma Aktiengesellschaft
High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
Uppsala University
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
Glaxosmithkline
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
Astrazeneca
Identification of selective inhibitors of cyclin dependent kinase 4.
Dupont Pharmaceuticals
Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.
Wyeth-Ayerst Research